RLAY - Relay Therapeutics Inc

https://www.relaytx.com

Hold Momentum: Bearish

Recent News

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

GlobeNewswire • 2 weeks, 3 days ago • score: -0.11

CAMBRIDGE, Mass., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Relay Therapeutics, Inc. ( Nasdaq: RLAY ) , a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will ...

Bullish

Relay Therapeutics ( RLAY ) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Commentary • 1 month ago • score: 0.31

Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Neutral

Relay Therapeutics, Inc. ( RLAY ) Reports Q2 Loss, Beats Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.08

Relay Therapeutics (RLAY) delivered earnings and revenue surprises of +16.33% and +35.40%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Neutral

RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?

Zacks Commentary • 1 month, 3 weeks ago • score: 0.09

Recursion Pharmaceuticals and Relay Therapeutics both leverage their respective AI drug discovery platforms to potentially develop novel therapeutic candidates.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-09 (Snapshot)

Relay Therapeutics, Inc. is a clinical-stage precision drug company. The company is headquartered in Cambridge, Massachusetts.

52W High

$10.72

52W Low

$1.78

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

1.60

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.80

EV/Revenue (<3 favorable)

10.50

P/S (TTM) (<3 favorable)

85.02

P/B (<3 favorable)

1.07

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

1.42%

Institutions (25–75% balanced)

100.38%

Shares Outstanding

172,411,000

Float

102,624,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

8,355,000

Gross Profit (TTM)

-267,972,000

EPS (TTM)

-1.91

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-110.11%

ROE (TTM) (>15% strong)

-0.46%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.23

Momentum

Bearish momentum

Value

0.1883

0.1993

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025